Oct 9, 2015
In Episode 56, Marshall Saunders speaks with Accredited Investor Markets Radio about SaundersDailey, a hyper-local real estate investment platform in Minneapolis-St. Paul, Minnesota. "Hyper-local" in that the deals arise only in the immediate locality known well by SaundersDailey, the platform also enables collective real estate investing and thus an individual accredited investor's access to bigger deals.
Find out more about Marshall Saunders and Saunders Dailey here.
Or you can find them here:
LinkedIn: Marshall Saunders; SaundersDailey
About Marshall Saunders
Marshall Saunders is co-founder and managing partner of SaundersDailey, an online investment marketplace connecting investors to exclusive real estate opportunities, with low minimum investments, in select markets throughout the Midwest. Heralded as a “Real Estate Tech Titan” by RIS Media, Marshall harnesses his two decades of traditional real estate experience and passion for technology to enable more people to participate in real estate investing in their local community.
Prior to founding SaundersDailey, Marshall held the coveted distinction of co-owner and broker of the largest RE/MAX franchise in the world. During his tenure, he developed a growth strategy that doubled the company from 450 Minneapolis-located agents to 900 agents across Minnesota and parts of Wisconsin. Under Marshall’s leadership, his firm also sold more listings than any other RE/MAX franchise in existence. His extensive experience in sales, brokerage and ownership positions grants him deep, first-hand industry knowledge on the micro and macro levels, as well as access to a valuable network of influential real estate executives.
Marshall is a nationally recognized industry leader in residential real estate and technology, and was named as one of Swanepoel’s “200 Most Powerful People in Residential Real Estate” in 2013. He is an active member in the community, where he currently serves on the University of Minnesota Foundation’s Vision 2017 board to help raise $1 billion for cancer and biotechnology research.